JP2013543881A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543881A5
JP2013543881A5 JP2013540410A JP2013540410A JP2013543881A5 JP 2013543881 A5 JP2013543881 A5 JP 2013543881A5 JP 2013540410 A JP2013540410 A JP 2013540410A JP 2013540410 A JP2013540410 A JP 2013540410A JP 2013543881 A5 JP2013543881 A5 JP 2013543881A5
Authority
JP
Japan
Prior art keywords
formulation
mesoporous silica
active ingredient
range
croscarmellose sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013540410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543881A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/071186 external-priority patent/WO2012072580A1/en
Publication of JP2013543881A publication Critical patent/JP2013543881A/ja
Publication of JP2013543881A5 publication Critical patent/JP2013543881A5/ja
Pending legal-status Critical Current

Links

JP2013540410A 2010-11-29 2011-11-28 秩序化したメソポーラスシリカの圧縮製剤 Pending JP2013543881A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10192938.8 2010-11-29
EP10192938 2010-11-29
PCT/EP2011/071186 WO2012072580A1 (en) 2010-11-29 2011-11-28 Compressed formulations of ordered mesoporous silicas

Publications (2)

Publication Number Publication Date
JP2013543881A JP2013543881A (ja) 2013-12-09
JP2013543881A5 true JP2013543881A5 (https=) 2014-03-06

Family

ID=43827090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540410A Pending JP2013543881A (ja) 2010-11-29 2011-11-28 秩序化したメソポーラスシリカの圧縮製剤

Country Status (6)

Country Link
US (1) US20130243833A1 (https=)
EP (1) EP2646005B1 (https=)
JP (1) JP2013543881A (https=)
ES (1) ES2744926T3 (https=)
PL (1) PL2646005T3 (https=)
WO (1) WO2012072580A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
EP3193836A1 (en) 2014-09-15 2017-07-26 PharmaSol GmbH Active-loaded particulate materials for topical administration
BR112021008732A2 (pt) 2018-11-07 2021-08-03 Disruptive Materials Pharma Ab ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592764B1 (en) * 1997-12-09 2003-07-15 The Regents Of The University Of California Block copolymer processing for mesostructured inorganic oxide materials
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
US20060018966A1 (en) 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
JP5519639B2 (ja) * 2008-04-28 2014-06-11 フォーマック ファーマシューティカルズ ナムローゼ フェンノートシャップ 秩序化したメソポーラスシリカ材料
DK2393485T3 (en) * 2009-02-06 2015-10-26 Gilead Sciences Inc Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir

Similar Documents

Publication Publication Date Title
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
JP2015007131A5 (https=)
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
NZ729172A (en) Combination formulation of two antiviral compounds
JP2007302683A5 (https=)
JP2010132654A5 (https=)
JP2015078230A5 (https=)
JP2010527347A5 (https=)
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
JP2016501828A5 (https=)
JP2014205701A5 (https=)
JP2010534220A5 (https=)
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
CN104661649A (zh) 包含替格瑞洛的固态口服医药制剂
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A
JP2015514739A5 (https=)
JP2013166781A5 (https=)
PH12014501408A1 (en) Immediate release multi unit pellet system
RU2015143475A (ru) Продукт и способ лечения диареи
JP2013543881A5 (https=)
JP2009542678A5 (https=)
PL2647637T3 (pl) Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
MX374106B (es) Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.
JP2011516544A5 (https=)
JP2015129124A5 (https=)